ChromaDex(US:CDXC)2025-05-07 20:41Financial Performance - Q1 2025 - Total company net sales reached $30.5 million, a 38% increase year-over-year (YoY)[10] - Tru Niagen® net sales were $21.5 million, up 24% YoY[10] - Niagen® ingredient sales increased significantly to $8.0 million, a 95% YoY increase[10] - Gross margin improved to 63.4%, a 270 basis points increase YoY[10] - Net income was $5.1 million, or $0.07 earnings per share, an increase of $5.6 million and $0.08 YoY[10] - Adjusted EBITDA was $4.9 million, up $4.2 million YoY[10] - The company ended the quarter with $55.6 million in cash and no debt, with cash provided from operations at $7.9 million year-to-date[10] Sales Mix - Q1 2025 - E-commerce accounted for 58% of net sales in Q1 2025, compared to 55% in Q1 2024[26] - Watson's & Other B2B represented 20% of net sales in Q1 2025, up from 16% in Q1 2024[26] - Food-grade Niagen® contributed 19% of net sales in Q1 2025, down from 23% in Q1 2024[26] - Tru Niagen® net sales accounted for 71% of total net sales in Q1 2025, compared to 78% in Q1 2024[27] - Niagen®-related net sales remained at 97% of total net sales in both Q1 2025 and Q1 2024[27] Financial Outlook - 2025 - The company adjusted its full-year 2025 net sales growth outlook to between 20%-25%, previously approximately 18%[10] - Adjusted general and administrative expenses outlook was revised upwards by $7.0 to $8.0 million, previously $5.0 to $6.0 million[10]